COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma (polymorphism)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03118869
Recruitment Status : Unknown
Verified August 2017 by Aliae AR Mohamed Hussein, Assiut University.
Recruitment status was:  Active, not recruiting
First Posted : April 18, 2017
Last Update Posted : August 28, 2017
Sponsor:
Information provided by (Responsible Party):
Aliae AR Mohamed Hussein, Assiut University

Brief Summary:

The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection, Enhanced mucociliary clearance.

The b2AR gene is located on chromosome 5q31-q32, a region that is genetically linked to asthma and related phenotypes. There are three best known polymorphisms in the coding region of the b2AR gene that can modulate the function of the receptor.


Condition or disease
Gene Abnormality Asthma

Detailed Description:

Asthma is a complex disease and has a strong genetic component in its pathogenesis. So far, considerable efforts have been made to evaluate the association between genetic variants and asthma risk, and numerous genes have been identified as asthma Reporting Items susceptible genes.

The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection, Enhanced mucociliary clearance.

The b2AR gene is located on chromosome 5q31-q32, a region that is genetically linked to asthma and related phenotypes. There are three best known polymorphisms in the coding region of the b2AR gene that can modulate the function of the receptor.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 75 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: B2adrenergic Receptor Gene Polymorphism in Bronchial Asthma: Relation to Disease Severity and Control
Actual Study Start Date : April 1, 2017
Estimated Primary Completion Date : October 1, 2017
Estimated Study Completion Date : October 30, 2017

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. To measure number of patient with homozygous and heterozygous B2AD gene polymorphisms with focus on Arg/Gly16 and Gln/Glu27 polymorphism [ Time Frame: 1 month ]
    study of prevalence homozygote and heterozygote patients


Secondary Outcome Measures :
  1. Number of patient with b2AR gene polymorphisms in different asthma severity and different response of treatment of asthma ( Arg/Gly16 and Gln/Glu27 polymorphism) [ Time Frame: 1 month ]
    correlation between polymorphism and pulmonary function test and level of disease control



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients diagnosed as asthma according to GINA 2016
Criteria

Inclusion Criteria:

  • patients diagnosed as asthma according to GINA guideline 2016.
  • Allergic asthma

Exclusion Criteria:

  • pneumonia
  • chronic cardiac, hepatic and renal diseases
  • pregnancy and lactation
  • malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118869


Locations
Layout table for location information
Egypt
AssiutU
Assiut, Egypt, 71111
Sponsors and Collaborators
Assiut University
Investigators
Layout table for investigator information
Principal Investigator: Aliae Mohamed-Hussein Professor of Pulmonology- Faculty of Medicine-Assiut University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Aliae AR Mohamed Hussein, Prof. Dr. Aliae AR Mohamed-Hussein, Professor of Pulmonology, Assiut University
ClinicalTrials.gov Identifier: NCT03118869    
Other Study ID Numbers: AssiutU3
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: August 28, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aliae AR Mohamed Hussein, Assiut University:
Asthma
B2 adrenergic receptors
Polymorphism
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases